one thing axiomat cover gener point
go whiff call trough given busi humbl say least
addit alopecia- gray hair-gener said though magnitud
amrx downward guidanc revis far larger thought could
believ inde repres trough myriad gener experienc competit
essenti wash year particularli context
cost save expect potenti come valu thesi
chang particularli bear mind new floor cost
save keep increas net debt/ebitda ratio turn reiter
overweight rate lower pt
chang manag note biggest factor downward
revis new ebitda guidanc rang
signific price pressur across portfolio word competit
intensifi myriad product higher-margin asset vagifem
voltaren gel regard two product specif manag certainli chang
tune regard suggest resili earlier year frustrat us
made suggest first place particularli consid
opaqu net price gener broader analyst/investor commun
part pattern manag team across gener space look
busi rose color glass said fair price dynam
gener product market fluid often chang rapidli even manag
great insight trend product appear
case voltaren gel product may resili earlier year
entri may chang price dynam rapidli dramat
leav capit structur actual much wors
instruct take closer look ebitda given impact
cost save mainli realiz major eros key gener
secondari product due competit year surmis
much way addit neg impact product
far less way product concentr risk compar year
impact new approv nuvar product
believ reason use middle-to-high end new ebitda guidanc rang
start point point ebitda around
layer cost save manag per convers
morn suggest save name portfolio ration
ebitda rang could modestli higher point net ebitda
versu mid-point previou guidanc rang
price competit risk gener product
amneal focus primarili gener market
price et
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
compani report factset pjc estim
page
consensu
compani report factset pjc estim
new pt base price-to-earnings unchang ep estim
discount unchang one year new pt translat
ebitda though admittedli premium major gener
group believ rel limit opioid-rel exposur visibl trough potenti
rebound ebitda favor debt matur schedul justifi higher multipl rel
revis estim reflect lower revenu amrx gener busi owe increas
competit across portfolio lower contribut amrx epinephrin auto-injector product
well modest contribut new product launch nod slower
pace approv dilut valu pipelin opportun due fewer limit competit
opportun power buyer consortium result dynam
lower gross margin estim estim also reflect cost save associ
page
million except per brand sale brand gener administr tax share amneal quarterli annual incom statement
million except ep
zomig brand sale
sale
sell gener administr
patent litig
incom loss tax
item net tax
expens revenu
sell gener administr
sell gener administr
ipxl began provid individu brand product sale earlier reflect pjc estim corepharma includ albenza emverm model reflect impact albenza gener competit start late
exclud cost relat remedi effort hayward ca manufactur facil
follow complet merger ameanl provid pro forma financi valu may reflect pjc estim
financi prior reflect legaci ipxl begin sale reflect amneal legaci ipxl sale
acquir part amneal acquisit gemini reflect pjc estim report net sale product
proprietari piper jaffray co juli
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
million
net chang asset liabil
acquisit intang
stock option issuanc
proprietari piper jaffray co juli
begin prior financi reflect ipxl
page
million
intang assets/oth estim reflect ipxl non-cash intang impair charg teva acquisit
reflect balanc sheet combin amneal entiti
proprietari piper jaffray co juli
page
